AI CAD Leader Heartflow is a global leader in AI-driven coronary artery disease management with a non-invasive platform that integrates Roadmap Analysis, FFRct Analysis, and Plaque Analysis, offering clinicians precise, early diagnosis and management. This positions the company well to expand partnerships with hospitals and cardiology centers seeking cutting-edge CAD care.

Broad Adoption With over 1,800 institutions already using Heartflow and more than 600,000 patients treated, there is demonstrated demand and a ready reference base to drive net-new sales through expansion into additional hospitals, health systems, and international markets.

Strong Reimbursement Narrative Heartflow’s platform aligns with ACC/AHA guidelines and has a strong track record in non-invasive coronary care, which can be leveraged to advocate for reimbursement coverage and faster adoption cycles within radiology and cardiology departments.

Financial Growth signals Recent Q1 2026 results show rising revenue and raised full-year guidance, signaling positive financial health and potential capacity for scaled deployments, managed services, and ongoing upsell of Plaque Analysis and CTA pathway solutions.

Strategic Partnerships With a global footprint (US, Europe, Japan) and existing enterprise focus, targeted partnerships with large health systems, medical device ecosystems, and software integrators present clear opportunities to broaden implementation and integrate Heartflow data into broader cardiovascular care platforms.